Artificial intelligence and open science in discovery of disease-modifying medicines for Alzheimer's disease

Feixiong Cheng; Fei Wang; Jian Tang; Yadi Zhou; Zhimin Fu; Pengyue Zhang; Jonathan L Haines; James B Leverenz; Li Gan; Jianying Hu; Michal Rosen-Zvi; Andrew A Pieper; Jeffrey Cummings

doi:10.1016/j.xcrm.2023.101379

Artificial intelligence and open science in discovery of disease-modifying medicines for Alzheimer's disease

Cell Rep Med. 2024 Feb 20;5(2):101379. doi: 10.1016/j.xcrm.2023.101379.

Authors

Feixiong Cheng¹, Fei Wang², Jian Tang³, Yadi Zhou⁴, Zhimin Fu⁵, Pengyue Zhang⁶, Jonathan L Haines⁷, James B Leverenz⁸, Li Gan⁹, Jianying Hu¹⁰, Michal Rosen-Zvi¹¹, Andrew A Pieper¹², Jeffrey Cummings¹³

Affiliations

¹ Genomic Medicine Institute, Lerner Research Institute, Cleveland Clinic, Cleveland, OH 44195, USA; Cleveland Clinic Genome Center, Lerner Research Institute, Cleveland Clinic, Cleveland, OH 44195, USA; Department of Molecular Medicine, Cleveland Clinic Lerner College of Medicine, Case Western Reserve University, Cleveland, OH 44195, USA. Electronic address: chengf@ccf.org.
² Department of Population Health Sciences, Weill Cornell Medical College, Cornell University, New York, NY 10065, USA.
³ Mila-Quebec Institute for Learning Algorithms and CIFAR AI Research Chair, HEC Montreal, Montréal, QC H3T 2A7, Canada.
⁴ Genomic Medicine Institute, Lerner Research Institute, Cleveland Clinic, Cleveland, OH 44195, USA.
⁵ Genomic Medicine Institute, Lerner Research Institute, Cleveland Clinic, Cleveland, OH 44195, USA; College of Pharmacy, Northeast Ohio Medical University, Rootstown, OH 44272, USA.
⁶ Department of Biostatistics and Health Data Science, Indiana University, Indianapolis, IN 46037, USA.
⁷ Cleveland Institute for Computational Biology, and Department of Population & Quantitative Health Sciences, Case Western Reserve University, Cleveland, OH 44106, USA.
⁸ Lou Ruvo Center for Brain Health, Neurological Institute, Cleveland Clinic, Cleveland, OH 44195, USA.
⁹ Helen and Robert Appel Alzheimer's Disease Research Institute, Brain and Mind Research Institute, Weill Cornell Medicine, New York, NY 10021, USA.
¹⁰ IBM Research, Yorktown Heights, New York, NY 10598, USA.
¹¹ AI for Accelerated Healthcare and Life Sciences Discovery, IBM Research Labs, Haifa 3498825, Israel; Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem 9190500, Israel.
¹² Brain Health Medicines Center, Harrington Discovery Institute, University Hospitals Cleveland Medical Center, Cleveland, OH, 44106, USA; Department of Psychiatry, Case Western Reserve University, Cleveland, OH 44106, USA; Geriatric Psychiatry, GRECC, Louis Stokes Cleveland VA Medical Center, Cleveland, OH 44106, USA; Institute for Transformative Molecular Medicine, School of Medicine, Case Western Reserve University, Cleveland OH 44106, USA; Department of Pathology, Case Western Reserve University, School of Medicine, Cleveland, OH, 44106, USA; Department of Neurosciences, Case Western Reserve University, School of Medicine, Cleveland, OH 44106, USA.
¹³ Chambers-Grundy Center for Transformative Neuroscience, Department of Brain Health, School of Integrated Health Sciences, UNLV, Las Vegas, NV 89154, USA.

Abstract

The high failure rate of clinical trials in Alzheimer's disease (AD) and AD-related dementia (ADRD) is due to a lack of understanding of the pathophysiology of disease, and this deficit may be addressed by applying artificial intelligence (AI) to "big data" to rapidly and effectively expand therapeutic development efforts. Recent accelerations in computing power and availability of big data, including electronic health records and multi-omics profiles, have converged to provide opportunities for scientific discovery and treatment development. Here, we review the potential utility of applying AI approaches to big data for discovery of disease-modifying medicines for AD/ADRD. We illustrate how AI tools can be applied to the AD/ADRD drug development pipeline through collaborative efforts among neurologists, gerontologists, geneticists, pharmacologists, medicinal chemists, and computational scientists. AI and open data science expedite drug discovery and development of disease-modifying therapeutics for AD/ADRD and other neurodegenerative diseases.

Publication types

Review

MeSH terms

Alzheimer Disease* / drug therapy
Artificial Intelligence
Drug Development
Drug Discovery
Electronic Health Records
Humans

Abstract

Publication types

MeSH terms

Grants and funding